Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine in Elderly AML (GOELAMS SA4)
NCT00925873Phase 3Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Jun 1996
- Primary completion
- Apr 2000
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fludarabine in acute myeloid leukemia (AML) (2 arms), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Event-free survival at 71 months. Started Jun 1996; status: completed.
02
Drugs
fludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00925873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00925873.